The COVID Variant That Emerged From the Shadows

Just when most Americans assumed COVID-19 had retreated to background noise, a new variant is drawing serious attention from public health officials. BA.3.2 — nicknamed “Cicada” by the scientific community — is a heavily mutated strain of SARS-CoV-2 that has been quietly spreading across the United States, now confirmed in at least 25 states by the U.S. Centers for Disease Control and Prevention (CDC).

The name is apt. Like the insects that lie dormant underground for years before emerging en masse, this variant simmered largely undetected after its first appearance, then began accelerating in fall 2025. Now, health experts are watching it closely — not because it appears more deadly, but because of something arguably more complex: its extraordinary ability to potentially sidestep your immune defenses.

From South Africa to San Francisco: The Cicada Timeline

Tracing the origin of BA.3.2 reveals an unusual trajectory — one that distinguishes it from recent dominant variants. While strains like XFG (Stratus) and NB.1.8.1 (Nimbus) descend from the JN.1 lineage, Cicada belongs to a completely different lineage. The CDC describes BA.3.2 as “genetically distinct” from the family of variants that has dominated the past two years.

The nickname “Cicada” was coined by T. Ryan Gregory, Ph.D., a professor of evolutionary biology at the University of Guelph, Canada — the same researcher who has named other variants including “Stratus” and “Pirola.” The name perfectly encapsulates the variant’s behavior: a long dormancy period followed by a sudden, widespread emergence.

What Makes BA.3.2 Different From Every Other Variant?

COVID variants come and go, and most make only incremental changes to the virus’s structure. Cicada is different in a way that demands scientific attention: it carries 70 to 75 mutations in its spike protein — the part of the virus that attaches to human cells and that vaccines are designed to target. That number is extraordinarily high.

The 2025-2026 COVID vaccine was formulated to target the JN.1 lineage — the backbone of most recent dominant variants. Since Cicada diverges dramatically from JN.1, early laboratory studies suggest the current vaccine may offer reduced protection against BA.3.2 infection. However — and this is critical — experts emphasize that vaccines still appear to protect against severe illness and hospitalization. The goal of COVID vaccination has always been to prevent the worst outcomes, not to eliminate infection entirely.

There is an interesting biological nuance that offers some reassurance. According to Dr. Pekosz and colleagues, some of Cicada’s mutations may actually make the virus bind less effectively to human cells. This could mean that while the variant evades immune recognition, it may also be less efficient at establishing infection — a biological trade-off that scientists are continuing to study.

COVID ‘Cicada’ Symptoms: What to Watch For in 2026

Here is the reassuring news on symptoms: according to the CDC and infectious disease physicians who have treated early BA.3.2 cases, the symptom profile of Cicada is consistent with other COVID-19 variants currently in circulation. There is no evidence that Cicada causes a unique constellation of symptoms, nor that it produces significantly worse illness in the general population.

That said, one symptom has been highlighted by clinicians as notably prominent in recent COVID infections: a severe sore throat, sometimes described as a “razorblade throat” sensation. Dr. Robert H. Hopkins Jr., Medical Director of the National Foundation for Infectious Diseases, specifically cited this as a common report alongside standard COVID symptoms.

Where Has Cicada Been Detected in the United States?

The CDC’s primary method for tracking BA.3.2 is wastewater surveillance — an approach that has proven far more sensitive than clinical testing alone, particularly as at-home testing has become more common and many mild cases go unreported. As of February 11, 2026, wastewater samples containing genetic signatures of BA.3.2 have been collected from 132 sites spanning at least 25 states.

It is important to put these detections in perspective. As of late March 2026, BA.3.2 represents approximately 0.55% of sequenced COVID cases in the United States — still a tiny fraction compared to the dominant variants XFG (Stratus) and NB.1.8.1 (Nimbus). However, the direction of the trend is what concerns epidemiologists: wastewater data from WastewaterSCAN, the Stanford University-led tracking program, found BA.3.2 in 11% of national samples during the week ending March 21, 2026 — a meaningful increase from 3.7% earlier in the month.

Is Cicada More Dangerous? What Experts Actually Say

The question every American rightly wants answered is: will this variant make people sicker? Based on all available evidence as of late March 2026, the answer is: not significantly so, compared to current circulating variants. Every known case of BA.3.2 in the United States has been relatively mild, and there has been no documented spike in deaths or hospitalizations linked specifically to this variant.

It is crucial, however, to place this reassurance in the right context. COVID-19 continues to kill approximately 100,000 Americans annually, with older adults, immunocompromised individuals, and those with underlying health conditions carrying the greatest burden of serious illness. Even a variant that is not inherently more severe can cause significant harm if it reinfects large numbers of people who previously had partial immunity.

One notable piece of good news: according to Adolfo Garcia-Sastre, Ph.D., a virologist at the Icahn School of Medicine at Mount Sinai, “The new variant is still sensitive to COVID antiviral drugs that we have been developing, so at least those will work.” Antivirals like Paxlovid and Lagevrio remain effective treatment options for eligible patients, particularly those at high risk of severe disease.

Who Should Be Most Vigilant About Cicada?

While the general public faces a currently low risk from BA.3.2, certain groups in the United States face meaningfully higher risk of serious outcomes from any COVID-19 infection. Public health officials and physicians urge these populations to take heightened precautions.

Dr. Hopkins delivered a sobering public health assessment: “Low vaccination rates and little to no public health effort toward stopping COVID infections and spread leaves us vulnerable.” This statement underscores a broader concern: the reduction of public health infrastructure and surveillance capacity since the official end of the COVID emergency may limit the US ability to respond rapidly if BA.3.2 gains significant traction.

What the CDC Recommends to Protect Yourself From Cicada

The fundamentals of COVID protection have not changed, even as the virus continues to evolve. The CDC and leading infectious disease physicians align on the following practical steps for all Americans — and especially for those in high-risk categories.

Will Cicada Become the Dominant Strain? What Comes Next?

The honest scientific answer is: we do not yet know. COVID-19 has repeatedly surprised even the world’s best epidemiologists. What can be said with confidence is that BA.3.2 has not yet shown the explosive global growth advantage that would mark it as clearly dominant. The WHO noted in early 2026 that despite its many mutations, BA.3.2 had not demonstrated “a sustained growth advantage over any other co-circulating variant.”

Even if Cicada can partially evade existing immunity, our immune systems are not starting from zero. Years of vaccination and prior infections have built layered immune responses that extend beyond antibody recognition alone. There will likely be some “cross-reactivity” — meaning our immune systems will still recognize some aspects of BA.3.2, even if the response is less robust than against known strains.

One concern raised by experts is the significant reduction in COVID surveillance infrastructure in the US. With fewer clinical tests being processed and reported, and reduced federal public health capacity, the country may be slower to detect a meaningful surge in BA.3.2 infections. Wastewater surveillance — the primary tool currently tracking this variant — provides directional signals but cannot capture the full clinical picture alone.

What Omisha Healthcare Advises for American Families

At Omisha Healthcare, our mission is to provide you with evidence-based health information that empowers real decisions — not panic, and not complacency. Here is our consolidated guidance based on the current state of BA.3.2 in the United States:

• ✓Do not panic. Current US prevalence of BA.3.2 remains low. The overall risk to healthy adults is low at this time. Monitor credible sources like the CDC website for updates.
• ✓Do stay informed. Check CDC wastewater data and your state health department for local updates on BA.3.2 prevalence in your area.
• ✓Do get vaccinated if you have not. The current vaccine still protects against severe disease. Talk to your doctor or pharmacist about whether a booster is recommended for you.
• ✓Do take symptoms seriously. If you develop COVID-like symptoms — especially that notable severe sore throat — test promptly. If high-risk, contact your provider about antivirals immediately.
• ✓Do protect vulnerable loved ones. If you live with or regularly see elderly family members, immunocompromised individuals, or others at high risk, take extra care — mask in crowded spaces, avoid them if you are symptomatic.
• ✗Do not dismiss it as “just a cold.” COVID continues to claim lives and cause Long COVID complications in a meaningful fraction of patients. Treat it with appropriate respect.
• ✗Do not assume past infection equals full protection. Cicada’s immune evasion profile means prior infection or vaccination may not fully protect against reinfection. Maintained precautions are wise, especially indoors with poor ventilation.